Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy Harrison

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
Journal of Medicinal Chemistry|May 30, 2003
Design and synthesis of highly potent benzodiazepine gamma-secretase inhibitors: preparation of (2S,3R)-3-(3,4-difluorophenyl)-2-(4-fluorophenyl)-4- hydroxy-N-((3S)-1-methyl-2-oxo-5- phenyl-2,3-dihydro-1H-benzo[e][1,4]-diazepin-3-yl)butyramide by use of an asymmetric Ireland-Claisen rearrangementIan Churcher, Susie Williams, Sonia Kerrad, et al.
Bioorganic & Medicinal Chemistry Letters|August 2, 2005
Cyclic sulfamide gamma-secretase inhibitorsTim Sparey, Dirk Beher, Jonathan Best, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 8, 2021
Cognitively Based Compassion Training for HIV Immune Nonresponders-An Attention-Placebo Randomized Controlled TrialBoghuma K Titanji, Mehul Tejani, Eugene W Farber, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 4, 2005
Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]Jonathan D Best, Mark T Jay, Franklin Otu, et al.
The New England Journal of Medicine|March 6, 2018
Quadrupling Inhaled Glucocorticoid Dose to Abort Asthma ExacerbationsTricia McKeever, Kevin Mortimer, Andrew Wilson, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|August 28, 2002
Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activityRachel K Conley, Michael J Cumberbatch, Glenn S Mason, et al.
Neurobiology of Aging|December 10, 2002
gamma-Secretase: characterization and implication for Alzheimer disease therapyMin Xu, Ming-Tain Lai, Qian Huang, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 28, 2002
A multicenter evaluation of the Biotest legionella urinary antigen EIATimothy Harrison, Søren Uldum, Stella Alexiou-Daniel, et al.
EMBO Reports|February 4, 2020
A revised model of TRAIL-R2 DISC assembly explains how FLIP(L) can inhibit or promote apoptosisLuke M Humphreys, Jennifer P Fox, Catherine A Higgins, et al.
Scientific Reports|September 20, 2022
Identification and development of a subtype-selective allosteric AKT inhibitor suitable for clinical developmentNatalie Page, Mark Wappett, Colin R O'Dowd, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Journal of Medicinal Chemistry|May 30, 2003
Design and synthesis of highly potent benzodiazepine gamma-secretase inhibitors: preparation of (2S,3R)-3-(3,4-difluorophenyl)-2-(4-fluorophenyl)-4- hydroxy-N-((3S)-1-methyl-2-oxo-5- phenyl-2,3-dihydro-1H-benzo[e][1,4]-diazepin-3-yl)butyramide by use of an asymmetric Ireland-Claisen rearrangementIan Churcher, Susie Williams, Sonia Kerrad, et al.
Bioorganic & Medicinal Chemistry Letters|August 2, 2005
Cyclic sulfamide gamma-secretase inhibitorsTim Sparey, Dirk Beher, Jonathan Best, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 8, 2021
Cognitively Based Compassion Training for HIV Immune Nonresponders-An Attention-Placebo Randomized Controlled TrialBoghuma K Titanji, Mehul Tejani, Eugene W Farber, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 4, 2005
Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]Jonathan D Best, Mark T Jay, Franklin Otu, et al.
The New England Journal of Medicine|March 6, 2018
Quadrupling Inhaled Glucocorticoid Dose to Abort Asthma ExacerbationsTricia McKeever, Kevin Mortimer, Andrew Wilson, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|August 28, 2002
Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activityRachel K Conley, Michael J Cumberbatch, Glenn S Mason, et al.
Neurobiology of Aging|December 10, 2002
gamma-Secretase: characterization and implication for Alzheimer disease therapyMin Xu, Ming-Tain Lai, Qian Huang, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 28, 2002
A multicenter evaluation of the Biotest legionella urinary antigen EIATimothy Harrison, Søren Uldum, Stella Alexiou-Daniel, et al.
EMBO Reports|February 4, 2020
A revised model of TRAIL-R2 DISC assembly explains how FLIP(L) can inhibit or promote apoptosisLuke M Humphreys, Jennifer P Fox, Catherine A Higgins, et al.
Scientific Reports|September 20, 2022
Identification and development of a subtype-selective allosteric AKT inhibitor suitable for clinical developmentNatalie Page, Mark Wappett, Colin R O'Dowd, et al.
Pageof 8